
|Videos|February 17, 2016
- Gastrointestinal Cancers: mCRC (Issue 7)
- Volume 1
- Issue 7
Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs
Author(s)Jonathan R. Strosberg, MD
The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Jonathan R. Strosberg, MD, medical oncologist, Moffitt Cancer Center, discusses the results of the phase III NETTER-1 trial. The trial looked at radionuclide therapy Lu-Dotatate (177Lutetium DOTATATE; Lutathera) in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Articles in this issue
almost 10 years ago
Neoadjuvant Therapy Continues to Evolve for Pancreatic Canceralmost 10 years ago
ERCC1 Expression Falls Short as Chemo Biomarker in mCRCalmost 10 years ago
Panitumumab Boosts Overall Survival in Chemorefractory mCRCalmost 10 years ago
Two Options Allows for Treatment Tailoring in Refractory CRCalmost 10 years ago
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRC



































